Dr. Josh Jang has a Ph.D. in molecular genetics and genomics from Washington University in St. Louis and a B.S. in health promotion and disease prevention from University of Southern California. His graduate work focused on characterizing transposable elements’ contribution to oncogenic potential in cancer cell line models, as well as other projects that established and optimized targeted epigenetic technologies using CRISPR-Cas9 technology. In 2020, Dr. Jang joined Van Andel Institute as a VAI Fellow under Drs. Peter A. Jones and Stephen S. Baylin.
Combinations of epigenetic therapies and immunotherapies have shown synergistic promise in treating both solid and blood cancers with varying degree of clinical response. The molecular mechanisms and biology driving the discrepancy in response to therapy are under heavy scrutiny in hopes of improving treatment efficacy. As part of the Van Andel Institute—Stand Up To Cancer Epigenetics Dream Team, we will explore the dynamism of the immune landscape at tumor microenvironment and cell state resolution using single-cell technologies to elucidate how patients’ immune system responds to epigenetic therapy (DNMTi) and immunotherapy (checkpoint blockade).
Ph.D. in molecular genetics and genomics, Washington University in St. Louis
Thesis: Epigenetic dynamics in normal and disease models
B.S. in health promotion and disease prevention, University of Southern California
Spencer T. and Ann W. Olin Fellow Award, Washington University in St. Louis (2020)
Poster Award, Cold Spring Harbor Asia, Systems Biology of Gene Regulation & Genome Editing (2018)
Presentation Award, Washington University in St. Louis, The Annual MGG/CSB/HSG retreat (2017)
T32 GM007067, NIGMS, Cellular and Molecular Biology Training Grant (2016)
Provost’s Undergraduate Research Fellowship, University of Southern California (2009, 2010)
To view a list of selected publications click below.
He Y*, Jang HS*, Xing X, Li D, Wang T. DeepH&M: In press. Estimate single-CpG hydroxymethylation and methylation from enrichment and restriction enzyme sequencing methods. Sci Adv.
Lee HJ, Hou Y, Chen Y, Daily Z, Riddihough A, Jang HS, Johnson SL, Wang T. 2020. Regenerating zebrafish fin epigenome is characterized by stable lineage-specific DNA methylation and dynamic chromatin accessibility. Genome Biol 21:52.
Choudhary MNK, Friedman RZ, Wang JT, Jang HS, Zhuo X, Wang T. 2020. Co-opted transposons help perpetuate conserved higher-order chromosomal structures. Genome Biol 21:16.
Pehrsson EC*, Jang HS*, Wang T. 2019. Epigenetic Alterations in Cancer. Cancer Genomics for the Clinician. Book
Jang HS*, Shah NM*, Du A, Zhu Z, Pehrsson EC, Godoy P, Zhang D, O’Donnell D, Kim S, Milbrandt J, Gordon JI, Wang T. 2019. Transposable elements drive widespread expression of oncogenes in human cancers. Nat Gen 51:611-617.
Zhou J*, Sears RL*, Xing X, Zhang B, Li B, Rockweiler NB, Jang HS, Choudhary MNK, Lee HJ, Lowdon RF, Arand J, Tabers B, Gu CC, Cicero TJ, Wang T. 2017. Tissue-specific DNA methylation is conserved across human, mouse, and rat, and driven by primary sequence conservation. BMC Genomics 18:724.
Brocks D*, Schmidt C*, Daskalakis M*, Jang HS, Shah NM, Li D, Li J, Zhang B, Hou Y, Laudato S, Lipka DB, Schott J, Bierhoff H, Assenov Y, Helf M, Ressnerova A, Islam MS, Lindroth AM, Haas Sm Essers M, Imbusch CD, Brors B, Oehme I, Witt O, Lubbert M, Mallm JP, Rippe K, Will R, Weichenhan D, Stoecklin G, Gerhauser C, Oakes CC, Wang T, Plass C. 2017. DNMT and HDAC inhibitors globally induce cryptic TSSs encoded in long terminal repeats. Nat Gen 49:1052-1060.
Lowdon RF, Jang HS, Wang T. 2016. Evolution of epigenetic regulation in vertebrate genomes. Trends Genet, 32(5):269-283.
Main BJ, Smith AD, Jang HS, Nuzhdin SV. 2013. Transcription start site evolution in Drosophila. Mol Biolo a Evol 30(8):1966-1974.
Jang HS, Ehrenreich IM. 2012. Genome-wide characterization of genetic variation in the unicellular, green alga Chlamydomonas reinhardtii. PLoS ONE 7(7).